Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
03 juin 2023 14h15 HE
|
Replimune Group Inc
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no...
Replimune to Present at the Jefferies Global Healthcare Conference
01 juin 2023 16h01 HE
|
Replimune Group Inc
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
25 mai 2023 17h00 HE
|
Replimune Group Inc
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
18 mai 2023 08h00 HE
|
Replimune Group Inc
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and...
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
09 mai 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune to Present at Two Upcoming Investor Conferences
08 mars 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
09 févr. 2023 08h00 HE
|
Replimune Group Inc
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline...
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
07 févr. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 janv. 2023 08h05 HE
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
04 janv. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...